Your browser doesn't support javascript.
loading
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
Rodriguez, B Leticia; Chen, Limo; Li, Yanli; Miao, Shucheng; Peng, David H; Fradette, Jared J; Diao, Lixia; Konen, Jessica M; Alvarez, Frank R Rojas; Solis, Luisa M; Yi, Xiaohui; Padhye, Aparna; Gibson, Laura A; Ochieng, Joshua K; Zhou, Xiaofei; Wang, Jing; Gibbons, Don L.
Afiliação
  • Rodriguez BL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Chen L; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Li Y; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Miao S; Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
  • Peng DH; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Fradette JJ; United of Texas (UT) Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • Diao L; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Konen JM; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Alvarez FRR; Department Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Solis LM; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Yi X; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Padhye A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Gibson LA; Bellicum Pharmaceuticals, Inc., Houston, TX, United States.
  • Ochieng JK; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Zhou X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Wang J; United of Texas (UT) Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Front Immunol ; 14: 1161869, 2023.
Article em En | MEDLINE | ID: mdl-37449205
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pulmao Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pulmao Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos